A detailed history of Group One Trading, L.P. transactions in Atossa Therapeutics, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 106,708 shares of ATOS stock, worth $126,982. This represents 0.01% of its overall portfolio holdings.

Number of Shares
106,708
Previous 115,249 7.41%
Holding current value
$126,982
Previous $101,000 90.1%
% of portfolio
0.01%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$0.8 - $1.89 $6,832 - $16,142
-8,541 Reduced 7.41%
106,708 $192,000
Q4 2023

Feb 14, 2024

SELL
$0.63 - $0.98 $9,756 - $15,176
-15,486 Reduced 11.85%
115,249 $101,000
Q3 2023

Nov 09, 2023

BUY
$0.74 - $1.35 $41,514 - $75,735
56,100 Added 75.17%
130,735 $96,000
Q2 2023

Aug 09, 2023

BUY
$0.6 - $1.28 $6,364 - $13,576
10,607 Added 16.57%
74,635 $94,000
Q1 2023

May 12, 2023

SELL
$0.59 - $0.91 $43,151 - $66,555
-73,138 Reduced 53.32%
64,028 $46,000
Q4 2022

Feb 09, 2023

BUY
$0.5 - $1.01 $57,512 - $116,175
115,025 Added 519.51%
137,166 $72,000
Q3 2022

Nov 09, 2022

BUY
$0.82 - $1.14 $18,155 - $25,240
22,141 New
22,141 $18,000
Q3 2021

Nov 12, 2021

SELL
$2.89 - $6.4 $4.75 Million - $10.5 Million
-1,644,488 Closed
0 $0
Q2 2021

Aug 10, 2021

BUY
$1.52 - $8.62 $2.5 Million - $14.2 Million
1,644,488 New
1,644,488 $10.4 Million
Q1 2021

May 12, 2021

SELL
$0.92 - $4.33 $92 - $433
-100 Closed
0 $0
Q4 2020

Feb 10, 2021

SELL
$0.85 - $2.43 $765 - $2,187
-900 Reduced 90.0%
100 $0
Q3 2020

Nov 12, 2020

SELL
$1.98 - $4.35 $396 - $869
-200 Reduced 16.67%
1,000 $2,000
Q2 2020

Aug 13, 2020

BUY
$1.04 - $4.05 $728 - $2,835
700 Added 140.0%
1,200 $5,000
Q3 2019

Nov 12, 2019

BUY
$1.96 - $2.52 $784 - $1,008
400 Added 400.0%
500 $1,000
Q2 2019

Aug 09, 2019

BUY
$2.03 - $3.58 $202 - $358
100 New
100 $0

Others Institutions Holding ATOS

About ATOSSA THERAPEUTICS, INC.


  • Ticker ATOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 126,624,000
  • Market Cap $151M
  • Description
  • Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...
More about ATOS
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.